

Marianna Avitabile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4958487/publications.pdf>

Version: 2024-02-01

12
papers

268
citations

1039880

9
h-index

1199470

12
g-index

12
all docs

12
docs citations

12
times ranked

482
citing authors

#	ARTICLE	IF	CITATIONS
1	HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. BMC Medical Genetics, 2019, 20, 37.	2.1	57
2	Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor suppressor. International Journal of Cancer, 2018, 143, 2828-2837.	2.3	54
3	Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. Cancer Research, 2020, 80, 382-393.	0.4	30
4	Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. Scientific Reports, 2015, 5, 11158.	1.6	26
5	A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. Molecular Cancer Therapeutics, 2018, 17, 1405-1415.	1.9	25
6	Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. Carcinogenesis, 2017, 38, 1011-1020.	1.3	17
7	Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. Genes, 2019, 10, 663.	1.0	14
8	Association of <i>PARP1</i> polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma. Journal of Cellular and Molecular Medicine, 2020, 24, 4072-4081.	1.6	12
9	Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma. Journal of Cancer, 2020, 11, 1495-1504.	1.2	11
10	Proteomic Alterations in Response to Hypoxia Inducible Factor $2\uparrow$ in Normoxic Neuroblastoma Cells. Journal of Proteome Research, 2016, 15, 3643-3655.	1.8	9
11	CD55 is a HIF- $2\uparrow$ marker with anti-adhesive and pro-invading properties in neuroblastoma. Oncogenesis, 2016, 5, e212-e212.	2.1	8
12	FGFR1 is a potential therapeutic target in neuroblastoma. Cancer Cell International, 2022, 22, 174.	1.8	5